The United States Patent and Trademark Office (USPTO) has issued patent US12583859B2, covering compounds and methods related to PRMT5 inhibitors. The patent, assigned to the California Institute of Technology, details compounds of formulas (I)-(V) and their utility in treating cancers and other diseases. The patent was granted on March 24, 2026, with a filing date of March 25, 2020, and includes 24 claims.

This patent grant signifies new intellectual property in the field of oncology drug development. While not a regulatory rule imposing obligations on other entities, it establishes exclusive rights for the assignee. Companies operating in the pharmaceutical and biotechnology sectors, particularly those researching or developing PRMT5 inhibitors, should be aware of this granted patent to ensure they do not infringe on the intellectual property rights of the California Institute of Technology.